Tirzepatide Rules The Day On Lilly Earnings Call
Robust Sales In Diabetes And Obesity, Plus Good Data In NASH
Lilly reports better than 50% sequential sales growth for Mounjaro, while Zepbound’s early launch has brought in $176m. The company also unveiled positive Phase IIb data with tirzepatide in NASH.
